Natera (NTRA)
(Real Time Quote from BATS)
$106.39 USD
+0.29 (0.27%)
Updated Jul 25, 2024 09:48 AM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Natera (NTRA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$120.18 | $160.00 | $70.00 | 13.27% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Natera comes to $120.18. The forecasts range from a low of $70.00 to a high of $160.00. The average price target represents an increase of 13.27% from the last closing price of $106.10.
Analyst Price Targets (17)
Broker Rating
Natera currently has an average brokerage recommendation (ABR) of 1.09 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.09 a month ago based on 17 recommendations.
Of the 17 recommendations deriving the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 88.24% and 11.76% of all recommendations. A month ago, Strong Buy made up 88.24%, while Buy represented 11.76%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NTRA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 14 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.09 | 1.09 | 1.09 | 1.09 | 1.09 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/13/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
5/10/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
4/8/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
4/5/2024 | Not Identified | Not Identified | Hold | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
3/6/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
2/28/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
2/20/2024 | Raymond James | Andrew Cooper | Strong Buy | Moderate Buy |
1/30/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
1/12/2024 | UBS | Dan Leonard | Not Available | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.09 |
ABR (Last week) | 1.09 |
# of Recs in ABR | 17 |
Average Target Price | $120.18 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.69 |